keyword
https://read.qxmd.com/read/38408288/impact-of-premedication-de-escalation-on-incidence-of-infusion-related-reactions-with-daratumumab
#1
JOURNAL ARTICLE
Donna Vazirnia, Alejandro Del Rio Verduzco, Scott A Soefje, Kristyn A Sanders, Tyler B Sandahl
PURPOSE: Daratumumab is an anti-CD38 monoclonal antibody used to treat multiple myeloma and light chain amyloidosis. Because daratumumab may cause reactions after intravenous or subcutaneous (SC) administration, the manufacturer labeling recommends administration of premedications before every dose. Given incidence of infusion reactions appears to be rare after cycle 1, in April 2022, the Mayo Clinic implemented a practice change in which premedications were omitted from all daratumumab order sets after completion of cycle 1...
February 26, 2024: JCO oncology practice
https://read.qxmd.com/read/38318126/ixazomib-based-frontline-therapy-followed-by-ixazomib-maintenance-in-frail-elderly-newly-diagnosed-with-multiple-myeloma-a-prospective-multicenter-study
#2
JOURNAL ARTICLE
Li Bao, Yu-Tong Wang, Peng Liu, Min-Qiu Lu, Jun-Ling Zhuang, Mei Zhang, Zhong-Jun Xia, Zhen-Ling Li, Ying Yang, Zhen-Yu Yan, Hong-Mei Jing, Fei Dong, Wen-Ming Chen, Yin Wu, He-Bing Zhou, Rong Fu, Yu-Ping Gong, Wen-Rong Huang, Yong-Qing Zhang
BACKGROUND: Frail elderly patients with newly diagnosed multiple myeloma (NDMM) have inferior survival and less benefit from high-dose therapies. This prospective study aimed to investigate the efficacy, safety, and quality of life (QoL) of induction treatment of ixazomib/lenalidomide/dexamethasone (IRd) and ixazomib/pegylated liposomal doxorubicin/dexamethasone (IDd) followed by ixazomib/dexamethasone (Id) maintenance therapy in frail, elderly patients with NDMM. METHODS: From July 2019 to December 2021, this non-randomized concurrent controlled clinical study enrolled 120 NDMM patients aged ≥65 years with frailty defined by the International Myeloma Working Group (IMWG) frailty score or Mayo geriatric scoring system...
February 2024: EClinicalMedicine
https://read.qxmd.com/read/38317364/-analysis-of-efficacy-and-safety-of-daratumumab-containing-regimen-in-relapsed-and-refractory-multiple-myeloma-patients
#3
JOURNAL ARTICLE
Q R Yu, X Zhou, H Y Wu, L M Hao, X M Li, Y P Zhong
Objective: To investigate the efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients with combination regimen of daratumumab. Methods: The clinical data of 42 RRMM patients admitted to Qingdao Municipal Hospital from December 2020 to November 2023 were retrospectively analyzed, which included 26 males and 16 females, with a median age of 59 (47, 82) years old. According to the number of courses of treatment with Daratumumab, patients were divided into three groups: long course group (≥9 courses, n =21), medium course group (7-8 courses, n =12), and short course group (≤6 courses, n =9)...
February 20, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/38309938/scleromyxedema-and-underlying-multiple-myeloma
#4
JOURNAL ARTICLE
Shruti Agrawal, Nelson Leung, Lisa Drage
No abstract text is available yet for this article.
February 2024: Mayo Clinic Proceedings
https://read.qxmd.com/read/38228628/mode-of-progression-in-smoldering-multiple-myeloma-a-study-of-406-patients
#5
JOURNAL ARTICLE
Nadine H Abdallah, Arjun Lakshman, Shaji K Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie A Gertz, Martha Q Lacy, Suzanne R Hayman, Francis K Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Leif Bergsagel, S Vincent Rajkumar
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
January 17, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38049319/-validation-of-the-prognostic-value-of-the-mayo-mass-and-r2-iss-staging-systems-in-patients-newly-diagnosed-with-multiple-myeloma-a-single-center-study
#6
JOURNAL ARTICLE
Y Xu, X X Shen, Y Y Jin, J Y Li, L J Chen, R Zhang
Objective: To evaluate the prognostic value of Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma (MM) . Methods: A total of 371 patients newly diagnosed with MM in Jiangsu Province Hospital were included in the study. Cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization (cIg-FISH) was performed to detect cytogenetic abnormality. Clinical characteristics were combined to analyze the disease stage and evaluate the prognosis. Results: There were 37 (10...
September 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/37961238/mode-of-progression-in-smoldering-multiple-myeloma-a-study-of-406-patients
#7
S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, Francis Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, P Leif Bergsagel
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
October 23, 2023: Research Square
https://read.qxmd.com/read/37752128/clinical-characteristics-and-outcomes-in-risk-stratified-patients-with-smoldering-multiple-myeloma-data-from-the-czech-republic-registry-of-monoclonal-gammopathies
#8
JOURNAL ARTICLE
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS)...
September 27, 2023: Blood Cancer Journal
https://read.qxmd.com/read/37731678/real-world-duration-of-use-and-dosing-frequency-of-daratumumab-in-patients-with-multiple-myeloma-in-the-united-states
#9
JOURNAL ARTICLE
Rafael Fonseca, Eric E Chinaeke, Niodita Gupta-Werner, Alex Z Fu, Shuchita Kaila
Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as a combination therapy for newly diagnosed multiple myeloma (MM) and as monotherapy and combination therapy for relapsed or refractory MM cases. We assessed the length of DARA use across lines of therapy and the probabilities of treatment discontinuation in patients with MM in the real-world. We used the deidentified Clinformatics Data Mart database from Optum to identify patients with MM (n=2124) who received DARA-containing treatment between November 1, 2015 and March 31, 2021 in the United States...
October 2023: Mayo Clinic Proceedings. Innovations, Quality & Outcomes
https://read.qxmd.com/read/37727707/reduction-rate-of-monoclonal-protein-as-a-useful-prognostic-factor-in-standard-risk-group-of-newly-diagnosed-multiple-myeloma
#10
JOURNAL ARTICLE
Min Liu, Jun-Yu Zhang
BACKGROUND: Multiple myeloma (MM) is a common hematologic malignancy that originates from a malignant clone of plasma cells. Solitary plasmacytoma, history of diabetes, and platelet count are considered as prognostic factors for MM. But some patients are still associated with much worse outcomes without any prognostic predictors. This study aimed to observe the reduction rate of monoclonal protein (M protein) after the first and fourth chemotherapy cycles, which is considered as a new prognostic factor for progression-free survival (PFS) in standard-risk group of newly diagnosed MM patients...
August 26, 2023: World Journal of Clinical Cases
https://read.qxmd.com/read/37591876/long-term-outcomes-of-allogeneic-stem-cell-transplant-in-multiple-myeloma
#11
JOURNAL ARTICLE
Walker M Schmidt, Nirosha D Perera, Francis K Buadi, Suzanne R Hayman, Shaji K Kumar, Angela Dispenzieri, David Dingli, Joselle Cook, Martha Q Lacy, Prashant Kapoor, Nelson Leung, Eli Muchtar, Rahma M Warsame, Taxiarchis Kourelis, Moritz Binder, Wilson I Gonsalves, William J Hogan, Morie A Gertz
Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many others. We retrospectively analyzed 85 patients diagnosed with MM who underwent allo SCT as frontline or salvage therapy between 2000 and 2022 at Mayo Clinic Rochester and examined patient outcomes and prognostic markers. Overall survival (OS), progression free survival (PFS), treatment related mortality (TRM), and relapse rates (RR) were estimated using the Kaplan Meier method and competing risk models...
August 18, 2023: Blood Cancer Journal
https://read.qxmd.com/read/37479753/trends-in-utilization-of-stored-cryopreserved-autologous-peripheral-hematopoietic-cells-intended-for-a-second-or-beyond-autologous-hematopoietic-cell-transplantation-in-patients-with-multiple-myeloma-a-single-center-experience
#12
JOURNAL ARTICLE
Farah Yassine, Mohamed A Kharfan-Dabaja, Athanasios Tsalantsanis, Vivek Roy, Abba C Zubair, Hemant S Murthy, Ernesto Ayala, Madiha Iqbal, Taimur Sher, Sikander Ailawadhi, Ricardo D Parrondo
Due to the advent of effective novel therapies for multiple myeloma (MM), the use of cryopreserved autologous peripheral blood hematopoietic cells (APBHC) for a salvage autologous transplant (auto-HCT) is in decline. We evaluated utilization trends and costs associated with cryopreserved APBHC in patients with MM. We retrospectively evaluated the clinicopathologic data from 440 patients with MM who underwent APBHC mobilization and collection at Mayo Clinic Florida between 2010 and 2019. Based on institution-specific charges as of May 2021, the cost of 1 session of APBHC collection/apheresis was $4,680 and the cost of 1 year of APBHC cryopreservation was $4,790 per patient...
July 21, 2023: Bone Marrow Transplantation
https://read.qxmd.com/read/37229535/understanding-high-risk-smoldering-multiple-myeloma
#13
REVIEW
Natalia Kreiniz, Morie A Gertz
Smoldering multiple myeloma (SMM) is an asymptomatic condition with heterogeneous biology and various risks of progression to symptomatic disease. The best-known risk stratification models are Mayo-2018, and IWWG based on tumor burden. Recently, the personalized risk assessment tool PANGEA was introduced. New markers of SMM progression, including genomic and immune characteristics of plasma cells (PCs) and tumor microenvironment, are under investigation, and some have been incorporated into traditional scoring systems...
May 25, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37152822/psychosocial-and-supportive-care-needs-of-individuals-with-advanced-myeloma
#14
JOURNAL ARTICLE
Suzanne Rowland, Robin Forbes, Doris Howell, Helen Kelly, Arta Taghavi Haghayegh, Maja Cardinale, Trisha Ramnanan, Samantha J Mayo
PURPOSE: The purpose of this qualitative study is to understand, from the patient's perspective, their experience of living with advanced multiple myeloma, the psychosocial impact, and needs for support in managing and adapting to this illness. METHODS: An interpretive descriptive approach was used. Individual semi-structured telephone interviews were conducted with each participant, which focused on eliciting their descriptions of psychosocial issues and concerns, as well as the supports they use for coping with cancer...
2023: Canadian Oncology Nursing Journal
https://read.qxmd.com/read/37145015/prognostic-evaluation-and-staging-optimization-of-the-mayo-additive-staging-system-mass-in-real-world-for-newly-diagnosed-multiple-myeloma-patients
#15
JOURNAL ARTICLE
Yongqin Cao, Yingying Gong, Xin Zhou, Chao Sun
OBJECTIVE: To explore the prognostic value of the Mayo Additive Staging System (MASS) in real-world patients with newly diagnosed multiple myeloma(MM). METHODS: The clinical data of 307 patients with newly diagnosed MM from August 2015 to June 2022 were retrospectively analyzed. Survival analysis was conducted for each subgroup according to the MASS. The MASS was compared to the original staging systems to evaluate its prognostic value. Patients in the high-risk group were further stratified...
December 2023: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/37067996/daratumumab-lenalidomide-and-daratumumab-pomalidomide-in-relapsed-lenalidomide-exposed-or-refractory-multiple-myeloma
#16
JOURNAL ARTICLE
Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher, Victoria R Alegria, Rahma M Warsame, Rafael Fonseca, Ahsan Rasheed, Wilson I Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Francis K Buadi, David Dingli, Suzanne R Hayman, Craig B Reeder, Asher A Chanan-Khan, Sikander Ailawadhi
Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone (DRd) to daratumumab plus pomalidomide and dexamethasone (DPd) in lenalidomide-exposed multiple myeloma. We identified 504 consecutive multiple myeloma patients who received daratumumab at Mayo Clinic between January 2015 and April 2019. We excluded patients who received daratumumab in the first line, received more than four lines of therapy prior to daratumumab use, did not receive lenalidomide prior to daratumumab, or had an unknown status of lenalidomide exposure, and patients who received daratumumab combinations other than DRd or DPd...
April 6, 2023: Anti-cancer Drugs
https://read.qxmd.com/read/37019896/prognostic-value-of-early-bone-marrow-mrd-status-in-car-t-therapy-for-myeloma
#17
JOURNAL ARTICLE
Radhika Bansal, Mizba Baksh, Jeremy T Larsen, Matthew A Hathcock, David Dingli, A Keith Stewart, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R Hayman, Rahma M Warsame, Rafael Fonseca, P Leif Bergsagel, Sikander Ailawadhi, Shaji K Kumar, Yi Lin
Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of MRD negative (MRDneg) status at this timepoint is unclear. We examined the impact of month 1 BM MRD status in MM patients who received CART at Mayo Clinic between 8/2016 and 6/2021. Among 60 patients, 78% were BM-MRDneg at month 1; and 85% (40/47) of these patients also had decreased to less than normal level of both involved and uninvolved free light chain (FLC < NL)...
April 5, 2023: Blood Cancer Journal
https://read.qxmd.com/read/36852120/multiple-myeloma-in-a-young-adult-with-renal-involvement
#18
Meriam Hajji, Samia Barbouch, Rim Goucha, Ezzeddine Abderrahim
Multiple myeloma (MM) results from malignant plasma cell disorder. It represents approximately 10% of hematological malignancies and it is typically diagnosed in the elderly with a median age of 70 years and has a steep increase in incidence with advancing age. N Engl J Med. 2004, 1860; Clin Interv Aging. 2020, 619. The incidence of MM has been increasing over time, mostly due to population aging. Mayo Clin Proc. 2010, 225 However, certain MMs are diagnosed at young age even under 40 years old (2%)...
February 2023: Clinical Case Reports
https://read.qxmd.com/read/36797276/artificial-intelligence-enabled-screening-strategy-for-drug-repurposing-in-monoclonal-gammopathy-of-undetermined-significance
#19
JOURNAL ARTICLE
Alexander J Ryu, Shaji Kumar, Angela Dispenzieri, Robert A Kyle, S Vincent Rajkumar, Thomas C Kingsley
Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia. Medications that modify progression risk have yet to be identified. To investigate, we leveraged machine-learning and electronic health record (EHR) data to screen for drug repurposing candidates. We extracted clinical and laboratory data from a manually curated MGUS database, containing 16,752 MGUS patients diagnosed from January 1, 2000 through December 31, 2021, prospectively maintained at Mayo Clinic...
February 17, 2023: Blood Cancer Journal
https://read.qxmd.com/read/36775698/yttrium-90-ibritumomab-tiuxetan-is-cost-effective-compared-to-bendamustine%C3%A2-%C3%A2-rituximab-in-low-grade-lymphomas
#20
JOURNAL ARTICLE
Muhamad Alhaj Moustafa, Bijan J Borah, James P Moriarty, Ruchita Dholakia, Liuyan Jiang, Ke Li, Thomas E Witzig, Bradford S Hoppe, Jennifer Peterson, James R Cerhan, Han W Tun
BACKGROUND: Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] is a CD20-targeted radio-immunotherapeutic agent. It has shown an excellent therapeutic activity with high tolerability against previously untreated follicular lymphoma (FL) and marginal zone B cell lymphoma (MZL). It is an attractive therapeutic option as the treatment schedule is short and convenient. The aim of our study is to determine the cost-effectiveness of (90)Y-IT in comparison to the standard-of-care bendamustine + rituximab (BR) in the first-line treatment of low-grade FL (LG-FL) and MZL in the real world...
January 26, 2023: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
94691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.